#antivenom-procurement

Issues, solutions, and case studies for antivenom-procurement

Found 4 nodes with this tag: 1 issue · 1 solution · 2 case studies

Issues 1

#00132Effective antivenom is unaffordable, unavailable, or reaches rural victims too late

Rural snakebite victims in low- and middle-income countries die from envenoming that existing antivenom could treat, because effective products are priced out of reach, commercially withdrawn, absent from remote clinics, or arrived too late — an access, market, and logistics fail

3 Solutions 0 Sub-issues

Solutions 1

#00137Guarantee the market: pooled procurement, subsidy, prequalification and regional manufacturing

Stabilise antivenom supply with guaranteed-volume pooled procurement, donor/government subsidy, WHO prequalification, and regional manufacturing — so effective, region-matched antivenom stays commercially viable and reaches clinics affordably.

Case studies

Case studies 2

Kaltungo, Gombe State, Nigeria

Success

EchiTAb Study Group; MicroPharm (UK) and Instituto Clodomiro Picado (Costa Rica); Nigerian health services · since 2005 · National

A counter-example to the FAV-Afrique collapse: effective, region-matched African antivenom developed and sustained through public-academic partnership rather than a purely commercial market. EchiTAb-G (ovine, monospecif…

Permanent restoration of blood coagulability 6h after 1 vial EchiTAb-G (Kaltungo pre-trial use, 2005)incoagulable blood on presentation → 146/182 patients (80%, 95% CI 74-85%)

1 source

Sub-Saharan Africa

Failed

Sanofi Pasteur (manufacturer) · until 2016 · Region

FAV-Afrique was a polyvalent antivenom covering ~10 snake species across sub-Saharan Africa, considered safe and effective. Sanofi Pasteur halted production in 2010 (last batch made 2014, expired June 2016) after sales…

Price per dose>US$100USD

Annual sales vs. disease burden by 2010fell to under 1% of burden (~3,000 cases treated)

$100 · 3 sources

communityfix.org